Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

Background: Three different tyrosine kinase inhibitors have been approved as first-line therapies for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer with similar overall survival. This study determined dynamic changes in quality of life (QoL) for patients using these therapies after controlling for potential confounders. Methods: From 2011 to 2016, we prospectively assessed the utility values and QoL scores of patients using the EuroQol five-dimension and World Health Organization Quality-of-Life – Brief questionnaires. QoL functions after initiation of treatment were estimated using a kernel-smoothing method. Dynamic changes in major determinants were repeatedly assessed for constructing mixed models. Results: A total of 344 patients were enrolled, with 934 repeated assessments. After controlling for performance status, disease progression, EGFR mutation subtype and other confounders, the mixed models showed significantly lower QoL scores for afatinib versus gefitinib in the physical, psychological and social domains, and 10 facets. The differences seemed to appear 10 months after initiation of treatment. In contrast, there was no significant difference between erlotinib and gefitinib in the scores of all domains and facets. Conclusion: QoL in patients receiving afatinib seemed to be lower than in those receiving gefitinib. Since the sample sizes in this study were relatively small, more studies are warranted to corroborate these results.

Download Full-text

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

Cancer ◽

10.1002/cncr.29132 ◽

2014 ◽

Vol 121 (6) ◽

pp. 883-892 ◽

Cited By ~ 30

Author(s):

Robert C. Doebele ◽

David Spigel ◽

Mustapha Tehfe ◽

Sachdev Thomas ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Chemotherapy

Download Full-text

Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.lba9007 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. LBA9007-LBA9007 ◽

Cited By ~ 3

Author(s):

Tony Mok ◽

Ying Cheng ◽

Xiangdong Zhou ◽

Ki Hyeong Lee ◽

Kazuhiko Nakagawa ◽

...

Keyword(s):

Egfr Mutation ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Daily News ◽

Phase Iii Trial ◽

Open Label Phase ◽

Final Text

The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Monday, June 5, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Download Full-text